Roche

At this year’s Opinion Festival in Paide, Estonia, the Roche’s team hosted a discussion titled “Where Are Working-Age Employees Disappearing To?”, focusing on how innovation, support systems and cooperation can help people with serious or chronic illnesses remain in work or return safely. Across the Baltics, we face the same challenge: our populations are aging, the working-age population is shrinking, and pressure on healthcare budgets is increasing. At the same time, our economies need people to stay active and productive for longer. Yet medical innovation and new, effective treatments often reach patients in Estonia, Latvia and Lithuania more slowly than in many other European countries. This makes it increasingly important to look at healthcare not only as a cost, but also as an investment in people, participation and economic resilience. The discussion highlighted: 💡A serious or chronic diagnosis does not automatically mean leaving working life. Capacity to work can change throughout treatment, so part-time work, flexible arrangements and gradual return should be possible. 💡Solutions need to be individual. The right balance between treatment and work should be found through cooperation between the patient, healthcare professionals and the employer. 💡The value of treatment should be considered more broadly than its direct cost. If an effective treatment helps someone recover faster, maintain a better quality of life or return to work sooner, its impact reaches far beyond the healthcare budget. 💡Responsibility cannot rest with the patient alone. Employers, healthcare professionals and the state all have a role in making the journey back to work easier and more coordinate. 💡Prevention, early diagnosis, timely access to treatment and maintaining people’s ability to work are not separate challenges. They are part of the same picture. We cannot stop our societies from ageing. But we can influence how long and how well people are able to live, work and contribute despite health challenges. 👍 👏 Thank you Maiu Maasi, Tuuli Seinberg, Maivi Parv, Rille Pihlak and the moderator Keret Einaste! And thank you to Opinion Festival for fostering and advancing a culture of open discussion.

Scientific breakthroughs only matter when they reach the patient. While our focus at Roche is on developing personalised treatments for eye conditions, that impact is delivered by the clinicians, surgeons and specialists on the frontlines of care. This #WorldOphthalmologistDay, we celebrate these experts. They are the critical link in our shared commitment to protecting global sight. #ProtectVision #VisionHealth #Roche #Ophthalmology

In recognition of Spinal Muscular Atrophy (SMA) Awareness Month, we’re passing the mic to people with SMA. In the first episode of their podcast, they share who they are, their experiences, and the conversations that inspired them to speak openly about life with SMA. It’s a reminder that while SMA is part of their stories, it does not define them. Listen to the first episode and join the conversation: https://spkl.io/60477zU4c #SMAAwarenessMonth #SMAMyWay

Deep data is only the first step. For clinical researchers, the real breakthrough in #ophthalmology happens when we translate that data together. At Roche pRED, Principal Scientist Siqing Yu (郁肆青) MD, PhD approaches challenging threats to vision by bringing the clinical perspective directly to the data table. As a clinician, her day-to-day work relies on an immediate, active partnership with data scientists, AI experts, and statisticians. This multidisciplinary environment ensures that clinical insights guide the data models, while advanced analytics refine the clinical path, turning vast datasets into tangible solutions for patients. Watch the video below to see this collaborative teamwork in action #InsideRocheRnD #pRED #TranslationalMedicine #ScienceLife

#WorldLungCancerDay В Україні рак легені залишається однією з головних причин смертності від онкологічних хвороб серед чоловіків. Тривалий час страх і стереотипи про відсутність доступної терапії зупиняли людей від своєчасного звернення до лікаря. У Всесвітній день боротьби з раком легені ми прагнемо нагадати: турбота про здоров'я починається з уваги до себе. Виявлення захворювання на ранніх стадіях відкриває значно більше можливостей для ефективної терапії та збереження якості життя. У Roche ми переконані: справжні зміни відбуваються тоді, коли наукові досягнення, державна політика та голос пацієнтів об'єднуються. Спільно з органами охорони здоров'я та пацієнтською спільнотою ми працюємо над розширенням доступу до необхідної допомоги. 🫁Розширення доступу: Завдяки Договорам керованого доступу пацієнти з раком легені на ранніх стадіях, які відповідають визначеним критеріям, отримують безоплатне лікування за кошт держави по всій Україні. 🤝Інвестиції та партнерство: Покрокова реалізація проєкту з локалізації виробництва онкопрепаратів в Україні — це наш внесок у розвиток медичної системи та запорука стабільного доступу пацієнтів до терапії. 📢Голос пацієнта: Ми постійно співпрацюємо з пацієнтськими організаціями, щоб покращувати кожен етап маршруту пацієнта. Якщо ви або ваші близькі перебуваєте в групі ризику — не відкладайте, проконсультуйтеся зі своїм лікарем вже сьогодні. #WorldLungCancerDay #HealthcarePartnerships #RocheUkraine #OncologyCare

Our new sequencing by expansion (SBX) technology relies on a smart nanopore sensor module that translates individual molecules into precise digital data. By utilizing 8 million tiny wells with advanced membrane technology, the system achieves remarkable speed and flexibility in DNA sequencing. See the technology in action: https://lnkd.in/dnZC7VJz (Roche's sequencing technology is currently for research use only.) #NextGenSequencing #Genomics #RocheSBX #BiotechInnovation

Developing tailored treatments for age-related macular degeneration (AMD) and diabetic retinopathy requires moving past static clinical observations to map real-time disease progression. At Roche pRED, Clinical Research Fellow Rachael Harlow MB BChir, MChD and her colleagues are leveraging our data infrastructure to address this challenge. By analysing massive datasets, including fluid samples collected directly during patient injections, and integrating artificial intelligence, they are working to identify specific retinal features, investigate predictive biomarkers, and map disease progression with unprecedented accuracy. This data-driven framework allows us to accelerate the discovery of targeted therapeutic options at every stage of the patient journey. In this episode of #InsideRocheRnD, we take a look at how our translational ophthalmology teams are transforming patient data into predictive clinical insights. #Ophthalmology #pRED #TranslationalMedicine #ScienceLife

We are no longer just hoping for breakthroughs in Alzheimer’s disease, we are seeing them become a reality. From advanced diagnostics that could save precious time, to new ways of crossing the blood brain barrier and delivering medicines directly to the brain, the landscape is shifting. #Alzheimers #Neuroscience #BrainHealth

What if sustainability became the starting point for your next big idea? 🌍💡 Real challenges, real teams, real responsibility. We're thrilled to welcome more than 60 interns from over 20 countries to our Global Internship Programme in Innovation & Sustainability (#IP2TIS)! Over the coming months, they'll work on real projects across Science & Innovation, Digital, Technology & AI, Society and Sustainability - transforming ideas into solutions that matter. Because meaningful impact isn't defined by years of experience. It's created when you're trusted to contribute, supported to grow, and empowered to make a difference. To our new #IP2TIS interns: We can't wait to see the future you'll help shape 🌱 Curious? See what #IP2TIS is all about. https://lnkd.in/dqVQZF3R #Roche #IP2TIS #RocheCareers #Innovation #Sustainability #TakeAction

Every milestone reflects our shared commitment to improving patients' lives. By advancing science and innovation, we continue doing now what patients need next. Thank you to our teams around the world whose dedication makes this possible. Read our CEO Thomas Schinecker's message below to learn more.